A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 8, 2010, Pages 1103-1106

  Wu, Shiyang ^a   Zhu, Zeyao ^a   He, Jiaying ^a   Luo, Xiaodi ^a   Xu, Jiasen ^a   Ren Heidenreich, Lifen ^a  

^a Guangzhou Technology Innovation Base   (China)

Author keywords

KRAS; liquidchip; mutant enriched PCR; somatic mutations

Indexed keywords

DNA FRAGMENT; ENZYME; FORMALDEHYDE; PARAFFIN;

ARTICLE; BACTERIAL GENE; CLINICAL ASSESSMENT; COLORECTAL CANCER; DIGESTION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; KRAS GENE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTO ONCOGENE; QUALITATIVE ANALYSIS; RELIABILITY; SAMPLE; SENSITIVITY ANALYSIS; SERUM; SOMATIC MUTATION; TISSUE; WILD TYPE;

CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; DNA; DNA MUTATIONAL ANALYSIS; GENES, RAS; HUMANS; LUNG NEOPLASMS; MUTATION; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 77955439879     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.227     Document Type: Article

References (14)

1. Lee SH, Lee JW, Soung YH, Kim HS, Park WS, Kim SY, et. al. BRAF and KRAS mutations in stomach cancer. Oncogene 2003;22:6942-6945
2. Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. N Engl J Med 2008;359:1834-1836
3. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et. al. K-ras mutations and benefit from Cetuximab in advanced colorectal cancer. N Engl J Med 2008;359: 1757-1765
4. Tsao M, Sakurada A, Cutz J, Zhu C, Kamel-Reid S, Squire J, et. al. Erlotinib in lung cancer molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144
5. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-1380
6. Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CH, et. al. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Duke's C colon cancer. Am J Gastroenterol 2000;95:2953-2957
7. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, et. al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13:2890-2896
8. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers G, Schrama JG, et. al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-572
9. Board R, Thelwell N, Ravetto P, Little S, Ranson M, Dive C, et. al. Multiplexed assays for detection of mutations in PIK3CA. Clin Chem 2008;54:757-760
10. Klebig F, Fischer C, Petri S, Gerull H, Wagener C, Tschentscher P. Limitations in molecular detection of lymph node micrometastasis from colorectal cancer. Diagn Mol Pathol 2007;16: 91-95
11. Ausch C, Buxhofer-Ausch V, Oberkanins C, Holzer B, Minai- Pour M, Jahn S, et. al. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn 2009;11:508-513
12. Hulse R, Kunkler P, Fedynyshyn J. Optimization of multiplexed bead-based cytokine immunoassays for rat serum and brain tissue. J Neurosci Method 2004;136:87-98.
13. Spiro A, Lowe M, Brown D. A bead-based method for multiplexed identification and quantitation of DNA sequences using flow cytometry. Appl Envir Microbiol 2000;6:4258-4265
14. Schmitt M, Bravo I, Snijders P, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006;44:504-512